HLA-C*03:04:01 and HLA-B*15:18:01 but not HLA-DQA1*05 associated with anti- tumor necrosis factor antibody formation in Taiwanese inflammatory bowel disease patients

Figure 1 Drug persistence of biologic agents. A: Overall inflammatory bowel disease cohort; B: Crohn’s disease cohort. Both determined according to a Kruskal-Wallis test; C: Kaplan-Meier analysis with log-rank test comparing drug persistence among biologic agents in the inflammatory bowel disease cohort.

Figure 2 Kaplan-Meier estimation of the rate of anti-drug antibodies development. A: Infliximab-treated group, stratified according to human leukocyte antigen (HLA)-C*03:04:01 carrier status; B: Infliximab-treated group, stratified according to HLA-DQA1*05 carrier status; C: Adalimumab-treated group, stratified according to HLA-B*15:18:01 carrier status; D: Adalimumab-treated group, stratified according to HLA-DQA1*05 carrier status. HLA: Human leukocyte antigen.

Figure 3 Spearman’s correlation between serum anti-drug antibodies titers and serum drug trough levels. A: Infliximab-treated group; B: Adalimumab-treated group. ADA: Anti-drug antibody.